uniQure N.V. $QURE Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lowered its holdings in shares of uniQure N.V. (NASDAQ:QURE) by 63.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,704 shares of the biotechnology company’s stock after selling 39,834 shares during the period. Y Intercept Hong Kong Ltd’s holdings in uniQure were worth $1,325,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Aberdeen Group plc raised its holdings in shares of uniQure by 24.2% in the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock valued at $38,345,000 after buying an additional 535,163 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in uniQure in the 2nd quarter valued at about $29,217,000. JPMorgan Chase & Co. raised its stake in uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after acquiring an additional 1,491,486 shares during the last quarter. Sofinnova Investments Inc. lifted its position in uniQure by 185.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after acquiring an additional 1,012,585 shares during the period. Finally, Ameriprise Financial Inc. grew its stake in shares of uniQure by 38.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after purchasing an additional 212,218 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Trading Down 4.0%

Shares of QURE stock opened at $22.72 on Friday. uniQure N.V. has a fifty-two week low of $7.76 and a fifty-two week high of $71.50. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The business has a fifty day simple moving average of $23.63 and a 200-day simple moving average of $28.33. The stock has a market cap of $1.42 billion, a P/E ratio of -5.18 and a beta of 0.68.

uniQure (NASDAQ:QURE) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. On average, analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on QURE. Mizuho decreased their price target on uniQure from $60.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, December 8th. Benchmark reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. Stifel Nicolaus cut their price target on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, December 11th. William Blair reiterated a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Finally, The Goldman Sachs Group reduced their price target on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $58.33.

Insider Buying and Selling

In other uniQure news, Director Robert Gut sold 25,613 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the sale, the director owned 32,342 shares in the company, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the sale, the director owned 20,439 shares in the company, valued at $557,575.92. This represents a 23.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 102,247 shares of company stock worth $2,839,298. 4.79% of the stock is owned by corporate insiders.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.